Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 2, 2009, Pages 307-315

  Ross, L L ^a   Rouse, E ^a   Gerondelis, P ^a   DeJesus, E ^b   Cohen, C ^c   Horton, J ^a   Ha, B ^a   Lanier, E R ^a   Elion, R ^d  

^a GLAXOSMITHKLINE   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Community Research Initiative ^*  (United States)

^d Whitman Walker Clinic   (United States)

Author keywords

Clonal analysis; K65R; Resistance; Thymidine analogue mutations

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; THYMIDINE DERIVATIVE; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLONAL VARIATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; POPULATION ABUNDANCE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 77950213338     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp419     Document Type: Article

References (25)

1. Palmer S, Boltz V, Martinson N et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103: 7094-9.
2. Palmer S, Boltz V, Maldarelli F et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006; 20: 701-10.
3. Parikh UM, Zelina S, Sluis-Cremer N et al. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007; 21: 1405-14.
4. Parikh UM, Bacheler L, Koontz D et al. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80: 4971-7.
5. Gallant JE, Rodriguez AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921-30.
6. Harrigan PR, Stone C, Griffin P et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000; 181: 912-20.
7. Parikh UM, Koontz DL, Chu CK et al. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49: 1139-44.
8. Garcia-Lerma JG, MacInnes H, Bennett D et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003; 77: 5685-93.
9. Khanlou H, Yeh V, Guyer B et al. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2005; 19: 135-40.
10. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Abstracts of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Abstract 51. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
11. Delaunay C, Brun-Vezinet F, Landman R et al. Comparative selection of the K65R and M184 V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol 2005; 79: 9572-8.
12. Ross L, Scarsella A, Raffanti S et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001; 17: 1107-15.
13. Mouroux M, Descamps D, Izopet J et al. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antivir Ther 2001; 6: 179-83.
14. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001; 6 Suppl 3: 25-44.
15. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.
16. Elion R, Cohen C, DeJesus E et al. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: a 48-week pilot study. HIV Clin Trials 2006; 7: 324-33.
17. Ross LL, Elion R, Lanier R et al. Modulation of K65R selection by zidovudine inclusion-analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). AIDS Res Hum Retroviruses 2009; 25: 665-72.
18. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-45.
19. Ait-Khaled M, Stone C, Amphlett G et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002; 16: 1686-9.
20. Moyle G, Higgs C, Teague A et al. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 2006; 11:73-8.
21. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther 2007; 12: 695-703.
22. Ross L, Gerondelis P, Liao Q et al. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naïve subjects treated with tenofovir/abacavir/lamivudine. Antivir Ther 2005; 10: S102.
23. Van Rompay KK, Johnson JA, Blackwood EJ et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 2007; 4: 25.
24. Kagan RM, Lee TS, Ross L et al. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Res 2007; 75: 210-8.
25. Silva JC, Miranda AC, Goncalves MF et al. Therapy-selected mutations at RT position 215 counteract selection of K65R in HIV-2-infected patients. Antivir Ther 2009; 14: S105.